U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C27H26N4O4S.2ClH.H2O
Molecular Weight 593.522
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EFATUTAZONE DIHYDROCHLORIDE MONOHYDRATE

SMILES

O.Cl.Cl.CN1C(COC2=CC=C(CC3SC(=O)NC3=O)C=C2)=NC4=CC=C(OC5=CC(C)=C(N)C(C)=C5)C=C14

InChI

InChIKey=JMFBDJASOQDDGR-UHFFFAOYSA-N
InChI=1S/C27H26N4O4S.2ClH.H2O/c1-15-10-20(11-16(2)25(15)28)35-19-8-9-21-22(13-19)31(3)24(29-21)14-34-18-6-4-17(5-7-18)12-23-26(32)30-27(33)36-23;;;/h4-11,13,23H,12,14,28H2,1-3H3,(H,30,32,33);2*1H;1H2

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C27H26N4O4S
Molecular Weight 502.585
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Efatutazone (CS-7017 or RS-5444) is a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist with antineoplastic properties. Mediated through activation of PPAR-gamma, this agent is capable of inducing cell differentiation and apoptosis, thereby leading to a reduction in cellular proliferation. Efatutazone was in clinical trials for the treatment of solid tumors however; its development has been discontinued.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P37231|||Q15179
Gene ID: 5468.0
Gene Symbol: PPARG
Target Organism: Homo sapiens (Human)
Target ID: P37231|||Q15179
Gene ID: 5468.0
Gene Symbol: PPARG
Target Organism: Homo sapiens (Human)
PubMed

PubMed

TitleDatePubMed
A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies.
2012 Nov 1
Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial.
2013 Jun
Patents

Patents

Sample Use Guides

Phase I trial: 0.10 to 1.15 mg PO twice daily.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:25:45 GMT 2023
Edited
by admin
on Fri Dec 15 16:25:45 GMT 2023
Record UNII
4AUO475Y7H
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
EFATUTAZONE DIHYDROCHLORIDE MONOHYDRATE
Common Name English
(±)-2,4-THIAZOLIDINEDIONE, 5-((4-((6-(4-AMINO-3,5-DIMETHYLPHENOXY)-1-METHYL-1H-BENZIMIDAZOL-2-YL)METHOXY)PHENYL)METHYL)-, DIHYDROCHLORIDE, MONOHYDRATE
Common Name English
CS-7017 MONOHYDRATE
Code English
2,4-THIAZOLIDINEDIONE, 5-((4-((6-(4-AMINO-3,5-DIMETHYLPHENOXY)-1-METHYL-1H-BENZIMIDAZOL-2-YL)METHOXY)PHENYL)METHYL)-, HYDROCHLORIDE, HYDRATE (1:2:1)
Systematic Name English
INOLITAZONE DIHYDROCHLORIDE MONOHYDRATE
Common Name English
2,4-THIAZOLIDINEDIONE, 5-((4-((6-(4-AMINO-3,5-DIMETHYLPHENOXY)-1-METHYL-1H-BENZIMIDAZOL-2-YL)METHOXY)PHENYL)METHYL)-, DIHYDROCHLORIDE, MONOHYDRATE
Common Name English
Code System Code Type Description
FDA UNII
4AUO475Y7H
Created by admin on Fri Dec 15 16:25:45 GMT 2023 , Edited by admin on Fri Dec 15 16:25:45 GMT 2023
PRIMARY
PUBCHEM
25009213
Created by admin on Fri Dec 15 16:25:45 GMT 2023 , Edited by admin on Fri Dec 15 16:25:45 GMT 2023
PRIMARY
CAS
1048002-36-3
Created by admin on Fri Dec 15 16:25:45 GMT 2023 , Edited by admin on Fri Dec 15 16:25:45 GMT 2023
PRIMARY
SMS_ID
100000175072
Created by admin on Fri Dec 15 16:25:45 GMT 2023 , Edited by admin on Fri Dec 15 16:25:45 GMT 2023
PRIMARY
Related Record Type Details
ANHYDROUS->SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY